HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CHPA interim prez

This article was originally published in The Rose Sheet

Executive Summary

Consultant and longtime board member Robert Donovan will assume leadership post Jan. 15 upon departure of President Michael Maves, MD. Donovan and his wife will take up residence in D.C. area while maintaining their Connecticut home. An OTC industry veteran with ties to supplement industry, Donovan accepted CHPA Chairman Michael Valentino's job offer Dec. 16, is slated to visit association's offices the week of Dec. 24 and begin work Jan 2. Currently president of the Council on Family Health, Donovan said he will remain involved with the nonprofit educational organization through his leadership role at CHPA but would turn over decision-making duties to CFH Chairman Arthur Hayes, MD. Search for Maves' permanent replacement expected to take about six months...

You may also be interested in...



CHPA President

FDA Senior Associate Commissioner for Communications and Constituent Relations Linda Suydam to head CHPA as president after leaving her post June 1. Suydam, who has worked for FDA for 21 years, has managed agency activities including orphan products, special health and women's health, FDA says. CHPA board member Robert Donovan has served as interim president since Jan. 15 following the departure of President Michael Maves, MD (1"The Rose Sheet" Dec. 24, 2001, In Brief)...

Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review

As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.

Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients

Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.

UsernamePublicRestriction

Register

RS009901

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel